

Therapy adherence after interdisciplinary tumour board discussion is associated with improved outcome in soft tissue sarcoma – a Charité Comprehensive Cancer Centre analysis.

Research article - Supplementary material

Annika Strönisch, Daniel Rau, Silvan Wittenberg, David Kaul, Georgios Koulaxouzidis, Robert Öllinger, Maximilian von Laffert, Armin Jarosch, Frederik Schäfer, Ulrich Keilholz, Lars Bullinger, Sven Märdian, Jana Striefler and Anne Flörcken

Content:

- Supplementary material Table 1 – Therapy and outcome
- Supplementary material Table 2 - Subgroup* analysis - Univariate survival analysis localised tumour stage for disease-specific overall and progression-free survival

SUPPLEMENTARY MATERIAL TABLE 1 Therapy and outcome

Administered therapy modality number n	Localised tumour stage n=188	Metastasised tumour stage n=33
Resection	170 (90.4%)	20 (60.6%)
primary resection	119 (63.3%)	5 (15.2%)
after neoadjuvant therapy	50 (26.6%)	5 (15.2%)
palliative	1 (0.5%)	10 (30.3%)
Chemotherapy	70 (37.2%)	27 (81.9%)
neoadjuvant	58 (30.9%)	5 (15.2%)
adjuvant	5 (2.7%)	1 (3.0%)
neoadjuvant and adjuvant	3 (1.6%)	1 (3.0%)
palliative	4 (2.1%)	20 (60.6%)
Radiotherapy	82 (43.6%)	7 (21.2%)
neoadjuvant	4 (2.1%)	-
adjuvant	77 (41.0%)	1 (3.0%)
palliative	1 (0.5%)	6 (18.2%)
Regional deep hyperthermia	51 (27.1%)	3 (9.1%)
neoadjuvant	47(25.0%)	3 (9.1%)
adjuvant	4 (2.1%)	-
Outcome after primary therapy	n=188	n=33
complete remission	146 (77.7%)	2 (6.1%)
partial remission	10 (5.3%)	5 (15.2%)
stable disease	2 (1.1%)	3 (9.1%)
progression	20 (10.6%)	19 (57.6%)
unknown	10 (5.3%)	4 (12.1%)
Outcome after curative intended surgery	n=168	n=10
R0-Status	136 (81.0%)	6 (60.0%)
R1-Status	22 (13.1%)	1 (10.0%)
Unclear or greater than R1	10 (5.9%)	3 (30.0%)

SUPPLEMENTARY MATERIAL TABLE 2 Subgroup* analysis - Univariate survival analysis localised tumour stage

Tumour-specific overall survival								
Variable	Log rank-test				Cox regression			
	Number of cases n	Events	Mean in years (95%-CI)	p-value	Beta	HR	95%-CI	p-value
Sex	78	14		p=0.65				
female	43		4.8 (4.1-5.4)		Ref.			
male	35		4.5 (3.8-5.2)		0.24	1.3	0.4-3.6	p=0.65
Age	78	14		p=0.98				
<60 years	38		4.6 (3.9-5.2)		Ref.			
>60 years	40		4.7 (4.0-5.4)		0.01	1.0	0.4-2.9	p=0.99
Localisation	78	14		p=0.03				
extremities	52		5.1 (4.6-5.6)		Ref.			
trunk	19		3.6 (2.4-4.8)		1.34	3.8	1.3-11.4	p=0.02
head/neck	7		3.6 (2.6-4.6)		0.26	1.3	0.2-10.8	p=0.80
Histologic grading	73	14		p=0.61				
Low-grade	3		3.4 (1.0-5.7)		Ref.			
High-grade	70		4.6 (4.1-5.1)		-0.53	0.6	0.8-4.5	p=0.61
Charlson comorbidity Index	78	14		p=0.22				
=2	58		4.9 (4.3-5.4)		Ref.			
>2	20		3.3 (2.5-4.2)		0.68	2.0	0.7-5.9	p=0.22
ECOG	60	13		p=0.22				
=0	51		4.5 (3.9-5.1)		Ref.			
≥1	9		3.3 (1.4-5.1)		0.79	2.2	0.6-8.1	p=0.23
R-status**	64	6		p<0.001				
R0	56		5.4 (5.1-5.7)		Ref.			
R1/R2/RX	8		3.2 (1.5-4.9)		2.84	17.0	3.1-93.7	p<0.01
Adherence to therapy recommendations	74	14		p<0.001				
Complete implementation	40		5.5 (5.2-5.8)		Ref.			
Partial implementation of 1 therapy modality	9		4.5 (3.1-5.9)		2.00	7.2	1.0-51.5	p=0.05
Omission of ≥1 therapy modality	8		2.4 (1.9-2.9)		2.10	8.0	1.1-58.5	p=0.04
Inability of therapy adherence	17		1.6 (1.0-2.2)		3.23	25.3	5.2-122.3	p<0.001

Progression-free survival									
Variable	Log rank-test				Cox regression				
	Number cases n	of	Events	Mean in years (95%-CI)	p-value	Beta	HR	95%-CI	p-value
Sex	74		30		p=0.31				
female	41			3.0 (2.2-3.7)		Ref.			
male	33			3.8 (2.9-4.6)		-0.39	0.7	0.3-1.4	p=0.31
Age	74		30		p=0.72				
<60 years	37			3.2 (2.4-4.0)		Ref.			
>60 years	37			3.5 (2.7-4.4)		-0.13	0.9	0.4-1.8	p=0.72
Localisation	74		30		p=0.06				
extremities	50			3.7 (3.0-4.4)		Ref.			
trunk	18			2.5 (1.2-3.7)		0.91	2.5	1.1-5.5	p=0.02
head/neck	6			2.5 (1.2-3.9)		0.40	1.5	0.4-5.1	p=0.52
Histologic grading	71		28		p=0.77				
Low-grade	3			3.4 (2.7-4.0)		Ref.			
High-grade	68					0.29	1.3	0.2-10.0	p=0.78
Charlson comorbidity Index	74		30		p=0.07				
=2	54			3.6 (3.0-4.3)		Ref.			
>2	20			2.1 (1.2-3.0)		0.69	2.0	0.9-4.3	p=0.08
ECOG	58		25		p=0.69				
=0	49			3.2 (2.5-3.9)		Ref.			
≥1	9			2.7 (0.9-4.5)		0.22	1.2	0.4-3.6	p=0.70
R-status**	61		20		p<0.01				
R0	53			4.1 (3.5-4.7)		Ref.			
R1/R2/RX	8			2.0 (0.7-3.4)		1.33	3.8	1.4-9.9	p<0.01
Adherence to therapy recommendations	74		30		p<0.001				
Complete implementation	41			4.5 (3.9-5.1)		Ref.			
Partial implementation of 1 therapy modality	9			2.0 (0.6-3.4)		1.90	6.7	2.3-19.6	p<0.001
Omission of ≥1 therapy modality	8			1.6 (1.0-2.3)		1.51	4.5	1.3-15.2	p=0.01
Inability of therapy adherence	16			1.0 (0.4-1.5)		2.80	16.4	6.3-42.8	p<0.001

Subgroup criteria: no therapy before tumour board presentation, recommendation of ≥2 therapy modalities

**Patients, who received a resection. CI Confidence interval